Vertex’s $4.9B bet; Layoffs at Novartis, Genentech, Sanofi; Star founders unveil new startups; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

There’s no boring day in biopharma, and this was especially true this week with multiple exclusives and scoops from the Endpoints team. See if you missed anything!

Vertex’s $4.9B bet

Hours after the rumors surfaced on Wednesday, Vertex announced it would pay $4.9 billion for Alpine Immune Sciences and its experimental drug povetacicept to treat IgA nephropathy, a kidney disease that’s attracted increasing interest ranging from big drugmakers to VCs. It marks Reshma Kewalramani’s first major deal as CEO, and the latest expansion in Vertex’s scientific focus.

Layoffs at Novartis, Genentech 

Several big drugmakers…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks